JASMINE KHACHATRIAN: Open Payments
NPI 1215564877 · SHERMAN OAKS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$855 in 30 payments from 15 companies in 2025. Trend: 2023 $601 · 2024 $1,184 · 2025 $855
Food & beverage: $849Education: $7
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 4 | $174 |
| Regeneron Healthcare Solutions, Inc. | 7 | $167 |
| Amgen Inc. | 3 | $78 |
| Janssen Biotech, Inc. | 2 | $61 |
| Botanix SB Inc | 2 | $57 |
| Arcutis Biotherapeutics, Inc. | 2 | $48 |
| ABBVIE INC. | 2 | $44 |
| Galderma Laboratories, L.P. | 1 | $41 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 1 | $33 |
| Novartis Pharmaceuticals Corporation | 1 | $32 |
Products named: DUPIXENT, Otezla, TREMFYA, SOFDRA, Zoryve, NEMLUVIO, Winlevi, COSENTYX.
Industry payments across CA — which companies pay providers there.
